PARIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company developing first-in-class drug candidates for the treatment of age-related degenerative diseases, today announced that abstracts highlighting the Company’s lead candidate, SARCONEOS (BIO101) will be presented at the 11th International Conference on Cachexia, Sarcopenia and Muscle Wasting, being held between December 7-9, 2018 in Maastricht, Netherlands.
Stanislas Veillet, Ph.D., chief executive officer of BIOPHYTIS stated, “We are pleased with these preclinical results that demonstrate SARCONEOS accelerates skeletal muscle cell differentiation from stem cells and increases their energetic metabolism. These specific effects, combined with the stimulation of muscle protein synthesis, explain the significant effect of SARCONEOS on muscle mass, muscle strength and mobility, in animal models of muscular dystrophies.”
Dr. Veillet continued, “In addition, we are pleased to announce the completion of patients recruitment in the SARA-OBS observational study of SARCONEOS. These patients will be eligible to participate to the SARA-INT double-blind, placebo controlled, randomized Phase 2b clinical study in sarcopenia in sites in both the U.S. and Europe. 9 clinical centers are now open in SARA-INT.”
Details of the oral and poster presentations are as follows:
Oral Presentation
Title: BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells
Presenter: Maria Serova, Ph.D.
Session: D. Late breaking clinical science & clinical trial update
Date/Time: Saturday, December 8, 2018 at 11:00 a.m. CEST
Location: Ceramique, Crowne Plaza Hotel, Netherlands
Poster Presentations
Title: BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells
Presenter: Maria Serova, Ph.D.
Poster: 4-11
Session: 5
Date/Time: Saturday 8th of December 2018, 11 AM
Location: Poster Area, Crowne Plaza Hotel, Netherlands
Title: Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind, placebo controlled, randomized clinical trial to evaluate safety and efficacy of SARCONEOS (BIO101)
Presenter: Waly Dioh, Ph.D.
Poster: P5-001
Session: 12
Date/Time: Sunday 9th of December 2018, 10 AM
Location: Poster Area, Crowne Plaza Hotel, Netherlands
About SARCONEOS
BIOPHYTIS's lead candidate, SARCONEOS, is a first-in-class drug candidate formulated to activate the MAS receptor for the treatment of neuromuscular diseases. SARCONEOS is currently being tested in a Phase 2b clinical trial to preserve muscle strength, performance and patient mobility in sarcopenia, a degenerative disease characterized by loss of muscle mass, quality, and strength associated with aging that affects up to 50 million elderly people. In addition, BIOPHYTIS is preparing for the clinical development of SARCONEOS in children with DMD, which received orphan drug designation in 2018 from both the FDA and EMA.
About BIOPHYTIS
BIOPHYTIS SA, founded in 2006, is a biotechnology company specializing in the development of drug candidates to treat the disabilities caused by age-related degenerative diseases. Our clinical-stage pipeline is comprised of SARCONEOS, a MAS receptor activator, to preserve mobility in sarcopenia and Duchenne muscular dystrophy (DMD) patients and MACUNEOS, a drug that binds PPAR to prevent vision loss in patients with dry age-related macular degeneration (AMD) and other degenerative eye diseases, including Stargardt disease.
BIOPHYTIS is based in Paris on the Sorbonne Université campus and in Cambridge, Massachusetts. BIOPHYTIS collaborates with expert scientists from several Sorbonne Université institutes including the Paris Seine Biology Institute, the Institute of Myology, and the Vision Institute.
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).
For more information: http://www.biophytis.com
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
Disclaimer
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Listing Prospectus upon the admission of Company’s shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf- france.org) or on BIOPHYTIS’ website (www.biophytis.com).
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.
| BIOPHYTIS | Citigate Dewe Rogerson | |
| Stanislas VEILLET | International media & Investors | |
| CEO | Laurence BAULT/Antoine DENRY | |
| contact@biophytis.com | Laurence.bault@citigatedewerogerson.com | |
| Tel: +33 (0) 1 44 27 23 00 | antoine.denry@citigatedewerogreson.com | |
| Tel: +33 (0)1 53 32 84 78 | ||
| Mob: +33(0)6 64 12 53 61 | ||
| LifeSci Public Relations | ||
| Cherilyn CECCHINI, M.D. | LifeSci Advisors | |
| U.S. Media Contact | Chris MAGGOS | |
| ccecchini@lifescipublicrelations.com | Managing Director, Europe | |
| Tel: +1 (646) 876 5196 | chris@lifesciadvisors.com | |
| Tel: +41 79 367 6254 |